Mechanistic experiments demonstrated that AF-SD exerted a dual therapeutic action by suppressing pro-inflammatory cytokines (TNF-α reduced by 55.5%; IL-6 reduced by 49.56%) while simultaneously upregulating the angiogenic factor VEGF (increased by 89.57%). Here, IL6 is linked to atrial fibrillation.